Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Electrocatalytic synthesis of black tin oxide nanomaterial as photothermal agent for cancer therapy" [Mater. Sci. Eng. C 108 (2020) 110350].

Biomaterials advances·2026
Same author

A yeast-based platform for etoposide production via yatein bioconversion.

Metabolic engineering communications·2026
Same author

A Systematic Review on Classification, Exposure Pathways of Micropollutants in the Aquatic Environment, and Its Associated Human Health Risks.

Journal of applied toxicology : JAT·2026
Same author

Light-Mediated Enhancement of Carbon Sequestration in Engineered <i>Spathiphyllum</i>.

ACS environmental Au·2026
Same author

Retraction notice to "Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications" [Biomedicine & Pharmacotherapy 162 (2023) 114687].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Measurement of terrestrial gamma exposure and radon mass exhalation rate in the soil samples of lower Kumaun Himalaya, India.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026

Related Experiment Video

Updated: Aug 11, 2025

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Key oncologic pathways inhibited by Erinacine A: A perspective for its development as an anticancer molecule.

Parteek Prasher1, Mousmee Sharma2, Amit Kumar Sharma1

  • 1Department of Chemistry, University of Petroleum & Energy Studies, Energy Acres, Dehradun 248007, India.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|February 3, 2023
PubMed
Summary

Erinacine A, a natural compound from Hericium erinaceus, shows promise as an anticancer agent. It triggers apoptosis, reduces cancer cell proliferation, and induces cell cycle arrest through complex signaling pathways.

Keywords:
Anticancer mechanismsApoptosisCancer signalling pathwaysErinacine A

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K

Related Experiment Videos

Last Updated: Aug 11, 2025

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K

Area of Science:

  • Natural Product Chemistry
  • Oncology
  • Pharmacology

Background:

  • Chemotherapy is a cornerstone of modern cancer treatment, often achieving stable disease.
  • Naturally derived molecules are increasingly explored as complementary cancer therapies.
  • Erinacine A, a metabolite from Hericium erinaceus, has demonstrated therapeutic potential.

Purpose of the Study:

  • To review the anticancer mechanisms of Erinacine A.
  • To update knowledge on signaling pathways regulated by Erinacine A in cancer.

Main Methods:

  • Preclinical research including in vitro and in vivo pharmacological studies.
  • Analysis of Erinacine A's effects on cancer cell signaling pathways.

Main Results:

  • Erinacine A induces apoptosis in cancer cells.
  • It reduces cancer cell proliferation and invasiveness.
  • Erinacine A causes oxidative stress and cell cycle arrest in cancer cells.

Conclusions:

  • Erinacine A exhibits significant anticancer properties by modulating key oncological signaling pathways.
  • Its ability to induce apoptosis, inhibit proliferation, and cause cell cycle arrest supports its potential as a chemotherapeutic agent.